Evidence map›Paper›PMID 41961141›Full record

ArticleMolecular biology reports2026

A novel recombinant arginine deiminase from Limosilactobacillus reuteri DSM 20016 demonstrates anticancer activity against colon cancer cells.

Darshali Pravin Thakker, Ravi Gor, Chandrasudan Ramamurthy, Satish Ramalingam, Rajnish Narayanan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Darshali Pravin ThakkerDepartment of Genetic Engineering, College of Engineering & Technology, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, Tamil Nadu, India.
Ravi GorDepartment of Genetic Engineering, College of Engineering & Technology, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, Tamil Nadu, India.
Chandrasudan RamamurthyDepartment of Genetic Engineering, College of Engineering & Technology, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, Tamil Nadu, India.
Satish RamalingamDepartment of Genetic Engineering, College of Engineering & Technology, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, Tamil Nadu, India.
Rajnish NarayananDepartment of Genetic Engineering, College of Engineering & Technology, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603 203, Tamil Nadu, India. knrmku@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColon cancer remains one of the most prevalent and aggressive malignancies, underscoring the demand for targeted and biologically safe therapeutic strategies. Arginine deiminase (ADI) has gained increasing interest as a potential anticancer agent due to its ability to modulate cellular arginine availability and inhibit tumor progression. METHODS AND

resultsIn this study, we evaluated the anticancer efficacy of a recombinant ADI derived from the probiotic bacterium Limosilactobacillus reuteri (LrADI) against HCT116 human colorectal cancer. LrADI exhibited potent, dose-dependent cytotoxicity with a half-maximal inhibitory concentration (IC

conclusionsCollectively, these findings demonstrate that LrADI exerts selective, multi-faceted anticancer effects through reduction in cell viability, cell migration, and apoptosis induction, with minimal impact on non-cancerous cells. Owing to its probiotic origin, safety profile, and potent activity, LrADI represents a promising candidate for further development as a therapeutic agent for colorectal cancer.

Indexed as

Antineoplastic AgentsColonic NeoplasmsHydrolasesLimosilactobacillus reuteriApoptosisCell MovementCell ProliferationCell SurvivalHCT116 CellsHumansRecombinant ProteinsAntineoplastic Agentsarginine deiminaseHydrolasesRecombinant ProteinsApoptosisArginine deiminaseArginine deprivation therapyColorectal cancerLimosilactobacillus reuteri

Identifiers

PMID41961141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.